Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 49-54

  Imamura, Yohei ^a   Azuma, Koichi ^a   Kurata, Seiji ^a   Hattori, Satoshi ^b   Sasada, Tetsuro ^c   Kinoshita, Takashi ^a   Okamoto, Masaki ^a   Kawayama, Tomotaka ^a   Kaida, Hayato ^a   Ishibashi, Masatoshi ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; FDG PET; NSCLC; OS; PFS; SUVmax

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; UFT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MEDICAL PARAMETERS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 78650212423     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.04.004     Document Type: Article

References (26)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 2002, 346:92-98.
2. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa S., Negoro S., et al. Randomized phase III study of cisplatin plus irrinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
3. Pieterman R.M., van Putten J.W., Meuzelaar J.J., Mooyaart E.L., Vaalburg W., Koeter G.H., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343:254-261.
4. Vansteenkiste J., Fischer B.M., Dooms C., Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004, 5:531-540.
5. Easmus J.J., Rohren E., Swisher S.G. Prognosis and reevaluation of lung cancer by positon emission tomography imaging. Proc Am Thorac Soc 2009, 171-179.
6. Um S.W., Kim H., Koh W.J., Suh G.Y., Chung M.P., Kwon O.J., et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol 2009, 4:1331-1336.
7. Weber W.A., Petersen V., Schmidt B., Tyndale-Hines L., Link T., Peschel, et al. Positron emission tomography in non-small-cell cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657.
8. Berghmans T., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC). J Thorac Oncol 2008, 3:6-12.
9. Lee K.H., Lee S.H., Kim D.W., Kang W.J., Chung J.K., Im S.A., et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small-cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006, 12:4232-4236.
10. Na I.I., Byun G.H., Kang H.J., Cheon G.J., Koh J.S., Kim C.H., et al. 18F-fluoro-deoxy-glicose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res 2008, 14:2036-2041.
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
12. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
13. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
14. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007, 98:1336-1343.
15. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
17. Kaida H., Ishibashi M., Fujii T., Kurata S., Ogo E., Tanaka M., et al. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device. Ann Nucl Med 2008, 22:95-101.
18. Buyse M., Thirion P., Carlson R.W., Burzkowski T., Molenberghs G., Piedbois P. Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-378.
19. Lara P.N., Redman M.W., Kelly K., Edelman M.J., Williamson S.K., Crowley J.J., et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer. Results from Southwest Oncology Group randomized trials. J Clin Oncol 2008, 26:463-467.
20. Gollob J.A., Bonomi P. Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology 2006, 20:10-18.
21. Vesselle H., Salskov A., Turcotte E., Wiens L., Schmidt R., Jordan C.D., et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008, 3:971-978.
22. Casali C, Cucca M, Rossi G, Barbieri F, Lacuzio L, Bagni B, et al. The variation of prognostic significance of maximum standardized uptake value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma. Lung Cancer; 2009 (Epub ahead of print).
23. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., Kim Y.K., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007, 62:214-219.
24. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998, 11:437-443.
25. Costelloe C.M., Macapinlac H.A., Nadewell J.E., Fitzgerald N.E., Mawlawi O.R., Rohren E.M., et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 2009, 50:340-347.
26. Tateishi U., Gamez C., Dawood S., Yeung H.W., Cristofanilli M., Macapinlac H.A. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008, 247:189-196.